The hysterectomy economics

Ayman Al‐Hendy, Michał Ciebiera, Iana Malasevskaia, Resham Tanna, Monika Bączkowska
In: Journal of Endometriosis and Pelvic Pain Disorders · 2024 · vol. 17(2) , pp. 109–112 · doi:10.1177/22840265241306163 · W4405675151
article OA: closed CC0
View on OpenAlex View at publisher

Abstract

Uterine fibromas are an incredibly common condition, affecting the quality of life of both individuals and the whole society and carrying significant direct and indirect costs. UFs are mostly benign tumors, which in many cases can be treated with pharmacological and minimally invasive methods. However, in a significant proportion of cases, patients undergo a hysterectomy, which is undeniably an effective, recurrence-free treatment option for uterine fibromas but also an extensive abdominal operation. The problem of the elevated number of performed hysterectomies should be highlighted. There is a substantial need for regulation changes on the hospital quota, a better costs transparency, and a shared decision-making. We should encourage the use of new drugs and minimally invasive surgery and limit the hysterectomy for cases when it cannot be avoided. If performing surgical procedure is difficult then not performing is even more difficult. The appropriateness of surgery is our goal.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (30)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK